
College student, 22, brushed off 2 common symptoms as a sinus infection before being diagnosed with CANCER
In September 2024, Breeze Hunter, 22, a student at Texas A&M University, felt like she was having a 'rubber band' pulling at her head and was rapidly losing weight.
However, she kept dismissing her changing body and constant pain as a persistent sinus infection, something she was prone to.
The young student recalled: 'I had a lot of fluid in my ears, which was causing the headaches. I went to a clinic a few times and they pretty much said it was a sinus infection.'
But a month later, she decided to visit the doctor's office on her campus after finding herself too weak to walk up a flight of stairs or even go to classes - where she underwent a blood test.
Realizing that Hunter was severely anemic - where the body lacks enough healthy red blood cells - doctors at the clinic urged her to go to an emergency room.
She then tried going to an ER close to her campus but since they were full, Hunter decided to visit The University of Texas Medical Branch Hospital in her hometown League City, Texas.
After multiple blood tests, Hunter and her family were finally told that she was suffering from high risk acute myeloid leukemia, an aggressive blood cancer and was admitted to MD Anderson Cancer Center, Houston.
She told TODAY.com: 'I told them that the headaches are still here. I'm very weak and had fatigue. They recommended doing a blood test.'
'I had many people coming in and saying, 'It's looking like a sign of leukemia, but we'll keep testing because it could be a bunch of other things'.
'I freaked out. I had no idea what leukemia was. I was like am I going to survive this? Or is it treatable?'
Acute myeloid leukemia affects the myeloid cells in the bone marrow which are responsible for maturing into red and white blood cells in the bloodstream.
Once turned cancerous, these cells move from the bone marrow into the blood and spread the disease to other parts of the body, including the lymph nodes, liver, spleen, brain and spinal cord.
When it affects the brain and spinal cord, it can cause symptoms like headaches and weakness in the body.
Unlike other cancers, there are no numbered stages of AML and it can progress in rapid speeds.
Some symptoms of AML include fatigue, feeling cold, dizziness, pale skin, shortness of breath, easy bruising and bleeding with no clear cause.
The exact causes are unclear, however, smoking, being overweight, radiation exposure and previous chemotherapy can increase risks of developing AML.
But many patients, like Breeze Hunter, don't fall into any of those categories.
In 2024, over 20,00 Americans were diagnosed with AML and about 11,200 people died from the condition.
Possible treatments often include chemotherapy, targeted therapy and at times stem cell transplantation (a medical procedure that replaces diseased or damaged blood-forming stem cells with healthy ones from a donor).
Within days of being diagnosed, Hunter underwent a bone marrow aspiration (a sample of the liquid part of bone marrow taken for testing) and a spinal tap (a sample of cerebrospinal fluid taken from the lower part of the spine).
The doctors at the MD Anderson Cancer Center also kept her in the hospital and placed her seven days of chemotherapy infusions along with an experimental cancer-fighting pill, which was part of a clinical trial.
Much to their surprise, doctors tested Hunter's bone marrow after 21 days of starting chemotherapy to see if the treatment worked and saw improvement.
She was then placed on a second seven-day round of the treatment and showed significant improvement.
'I was supposed to get at least six rounds,' Hunter said. 'The chemo worked so well I only had to do two.'
According to her now-viral TikTok page, the college student was on a six-month chemotherapy plan that ended earlier this year.
After undergoing 11 rounds of radiation to kill any possible lingering cancer cells in her brain and spine plus an new intense round of chemotherapy, she received a stem cell transplant from her 21-year-old brother, Roy.
A stem cell transplant, also known as a bone marrow transplant, replaces damaged or diseased bone marrow with healthy stem cells that can develop into different types of blood cells.
It is done to treat various conditions, including certain cancers, blood disorders, and autoimmune diseases.
'I got a radiation/chemo burn all over my body, which was very very painful and I was pretty much burnt all over,' she said. The chemotherapy regimen 'was harder than the leukemia one.'
Following the transplant, she has remained in the hospital for to make sure everything went well and protect her from potential infection from her weakened immune system.
'Probably towards the end I was over it. I was like, 'I can't do this. This is too much,' Hunter recalled. 'It was very hard at times but God's watching me. So, I knew I was going to be OK.'
Since the end of her intense treatment, Hunter is now in remission and claims to feel better as well as stronger and intends to walk in her college graduation soon.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


North Wales Chronicle
an hour ago
- North Wales Chronicle
AstraZeneca unveils plans for £37bn investment in US amid tariff threats
The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'

Leader Live
2 hours ago
- Leader Live
AstraZeneca unveils plans for £37bn investment in US amid tariff threats
The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'


South Wales Guardian
4 hours ago
- South Wales Guardian
AstraZeneca unveils plans for £37bn investment in US amid tariff threats
The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'